212 related articles for article (PubMed ID: 16731953)
1. Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus.
Le Pogam S; Kang H; Harris SF; Leveque V; Giannetti AM; Ali S; Jiang WR; Rajyaguru S; Tavares G; Oshiro C; Hendricks T; Klumpp K; Symons J; Browner MF; Cammack N; Nájera I
J Virol; 2006 Jun; 80(12):6146-54. PubMed ID: 16731953
[TBL] [Abstract][Full Text] [Related]
2. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479.
Ali S; Leveque V; Le Pogam S; Ma H; Philipp F; Inocencio N; Smith M; Alker A; Kang H; Najera I; Klumpp K; Symons J; Cammack N; Jiang WR
Antimicrob Agents Chemother; 2008 Dec; 52(12):4356-69. PubMed ID: 18838588
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796.
Howe AY; Cheng H; Johann S; Mullen S; Chunduru SK; Young DC; Bard J; Chopra R; Krishnamurthy G; Mansour T; O'Connell J
Antimicrob Agents Chemother; 2008 Sep; 52(9):3327-38. PubMed ID: 18559648
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanism of a thumb domain hepatitis C virus nonnucleoside RNA-dependent RNA polymerase inhibitor.
Howe AY; Cheng H; Thompson I; Chunduru SK; Herrmann S; O'Connell J; Agarwal A; Chopra R; Del Vecchio AM
Antimicrob Agents Chemother; 2006 Dec; 50(12):4103-13. PubMed ID: 16940072
[TBL] [Abstract][Full Text] [Related]
5. Genotypic and phenotypic analyses of hepatitis C virus variants observed in clinical studies of VX-222, a nonnucleoside NS5B polymerase inhibitor.
Jiang M; Zhang EZ; Ardzinski A; Tigges A; Davis A; Sullivan JC; Nelson M; Spanks J; Dorrian J; Nicolas O; Bartels DJ; Rao BG; Rijnbrand R; Kieffer TL
Antimicrob Agents Chemother; 2014 Sep; 58(9):5456-65. PubMed ID: 24982088
[TBL] [Abstract][Full Text] [Related]
6. Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
Flint M; Mullen S; Deatly AM; Chen W; Miller LZ; Ralston R; Broom C; Emini EA; Howe AY
Antimicrob Agents Chemother; 2009 Feb; 53(2):401-11. PubMed ID: 18936191
[TBL] [Abstract][Full Text] [Related]
7. Cross-genotypic examination of hepatitis C virus polymerase inhibitors reveals a novel mechanism of action for thumb binders.
Eltahla AA; Tay E; Douglas MW; White PA
Antimicrob Agents Chemother; 2014 Dec; 58(12):7215-24. PubMed ID: 25246395
[TBL] [Abstract][Full Text] [Related]
8. Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors.
Herlihy KJ; Graham JP; Kumpf R; Patick AK; Duggal R; Shi ST
Antimicrob Agents Chemother; 2008 Oct; 52(10):3523-31. PubMed ID: 18694956
[TBL] [Abstract][Full Text] [Related]
9. A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors.
Chase R; Skelton A; Xia E; Curry S; Liu S; McMonagle P; Huang HC; Tong X
Antiviral Res; 2009 Nov; 84(2):178-84. PubMed ID: 19747948
[TBL] [Abstract][Full Text] [Related]
10. In vitro selection and characterization of HCV replicons resistant to multiple non-nucleoside polymerase inhibitors.
Delang L; Vliegen I; Leyssen P; Neyts J
J Hepatol; 2012 Jan; 56(1):41-8. PubMed ID: 21703175
[TBL] [Abstract][Full Text] [Related]
11. In vitro resistance study of AG-021541, a novel nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase.
Shi ST; Herlihy KJ; Graham JP; Fuhrman SA; Doan C; Parge H; Hickey M; Gao J; Yu X; Chau F; Gonzalez J; Li H; Lewis C; Patick AK; Duggal R
Antimicrob Agents Chemother; 2008 Feb; 52(2):675-83. PubMed ID: 18070954
[TBL] [Abstract][Full Text] [Related]
12. Preclinical characterization of GS-9669, a thumb site II inhibitor of the hepatitis C virus NS5B polymerase.
Fenaux M; Eng S; Leavitt SA; Lee YJ; Mabery EM; Tian Y; Byun D; Canales E; Clarke MO; Doerffler E; Lazerwith SE; Lew W; Liu Q; Mertzman M; Morganelli P; Xu L; Ye H; Zhang J; Matles M; Murray BP; Mwangi J; Zhang J; Hashash A; Krawczyk SH; Bidgood AM; Appleby TC; Watkins WJ
Antimicrob Agents Chemother; 2013 Feb; 57(2):804-10. PubMed ID: 23183437
[TBL] [Abstract][Full Text] [Related]
13. Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase.
Kukolj G; McGibbon GA; McKercher G; Marquis M; Lefèbvre S; Thauvette L; Gauthier J; Goulet S; Poupart MA; Beaulieu PL
J Biol Chem; 2005 Nov; 280(47):39260-7. PubMed ID: 16188890
[TBL] [Abstract][Full Text] [Related]
14. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors.
McCown MF; Rajyaguru S; Le Pogam S; Ali S; Jiang WR; Kang H; Symons J; Cammack N; Najera I
Antimicrob Agents Chemother; 2008 May; 52(5):1604-12. PubMed ID: 18285474
[TBL] [Abstract][Full Text] [Related]
15. Characterization of resistance to the nonnucleoside NS5B inhibitor filibuvir in hepatitis C virus-infected patients.
Troke PJ; Lewis M; Simpson P; Gore K; Hammond J; Craig C; Westby M
Antimicrob Agents Chemother; 2012 Mar; 56(3):1331-41. PubMed ID: 22203605
[TBL] [Abstract][Full Text] [Related]
16. Selection of replicon variants resistant to ACH-806, a novel hepatitis C virus inhibitor with no cross-resistance to NS3 protease and NS5B polymerase inhibitors.
Yang W; Zhao Y; Fabrycki J; Hou X; Nie X; Sanchez A; Phadke A; Deshpande M; Agarwal A; Huang M
Antimicrob Agents Chemother; 2008 Jun; 52(6):2043-52. PubMed ID: 18411324
[TBL] [Abstract][Full Text] [Related]
17. Preclinical characterization of JTK-853, a novel nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase.
Ando I; Adachi T; Ogura N; Toyonaga Y; Sugimoto K; Abe H; Kamada M; Noguchi T
Antimicrob Agents Chemother; 2012 Aug; 56(8):4250-6. PubMed ID: 22615294
[TBL] [Abstract][Full Text] [Related]
18. Mechanistic characterization of GS-9190 (Tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase.
Shih IH; Vliegen I; Peng B; Yang H; Hebner C; Paeshuyse J; Pürstinger G; Fenaux M; Tian Y; Mabery E; Qi X; Bahador G; Paulson M; Lehman LS; Bondy S; Tse W; Reiser H; Lee WA; Schmitz U; Neyts J; Zhong W
Antimicrob Agents Chemother; 2011 Sep; 55(9):4196-203. PubMed ID: 21746939
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor.
Kati W; Koev G; Irvin M; Beyer J; Liu Y; Krishnan P; Reisch T; Mondal R; Wagner R; Molla A; Maring C; Collins C
Antimicrob Agents Chemother; 2015 Mar; 59(3):1505-11. PubMed ID: 25534735
[TBL] [Abstract][Full Text] [Related]
20. Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase.
Lemm JA; Liu M; Gentles RG; Ding M; Voss S; Pelosi LA; Wang YK; Rigat KL; Mosure KW; Bender JA; Knipe JO; Colonno R; Meanwell NA; Kadow JF; Santone KS; Roberts SB; Gao M
Antimicrob Agents Chemother; 2014 Jun; 58(6):3485-95. PubMed ID: 24733465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
